INT257453

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.20
First Reported 2007
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 6.70
Pain Relevance 0.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

vesicle-mediated transport (USE1) endoplasmic reticulum (USE1) lysosome (USE1)
Anatomy Link Frequency
groove 1
foot 1
kidney 1
USE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 4 99.52 Very High Very High Very High
fibrosis 54 98.88 Very High Very High Very High
Multiple sclerosis 2 98.56 Very High Very High Very High
agonist 9 95.36 Very High Very High Very High
antidepressant 39 89.00 High High
palliative 5 73.28 Quite High
Infliximab 65 66.16 Quite High
Serotonin 9 59.60 Quite High
imagery 12 54.60 Quite High
Central nervous system 5 54.48 Quite High
Disease Link Frequency Relevance Heat
Malignant Neoplastic Disease 24 100.00 Very High Very High Very High
Apoptosis 14 98.96 Very High Very High Very High
Sleep Disorders 10 98.92 Very High Very High Very High
Nephrogenic Fibrosing Dermopathy 56 98.88 Very High Very High Very High
Sarcoma 140 98.56 Very High Very High Very High
Demyelinating Disease 3 98.56 Very High Very High Very High
Rigor 3 97.56 Very High Very High Very High
Leiomyosarcoma 26 96.78 Very High Very High Very High
Anaemia 68 95.92 Very High Very High Very High
Diabetic Foot Ulcer 54 95.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In France, use of medicinal products which do not have marketing authorisation and which is outside the context of a clinical trial is dependent on prior 'temporary authorisation for use' (ATU) being granted by the French Health Products Agency (Afssaps) [9,10].
Positive_regulation (dependent) of use
1) Confidence 0.20 Published 2010 Journal Trials Section Body Doc Link PMC2997627 Disease Relevance 0.38 Pain Relevance 0
This off-label use of medicines in children has however been an increasing concern over the last decade leading to recognize that such situation was unethical as children have not access to medications properly assessed.
Positive_regulation (increasing) of use
2) Confidence 0.13 Published 2008 Journal Child Adolesc Psychiatry Ment Health Section Body Doc Link PMC2629463 Disease Relevance 0 Pain Relevance 0
Recently, gemcitabine and docetaxel have proven efficacious in the treatment of LMS and undifferentiated pleomorphic high grade sarcoma, and have been increasingly used as a first line regimen in these histologic subtypes.11 Investigators have evaluated the use of pegylated liposomal doxorubicin (PLD) in several phase II clinical trials, trying to capture the efficacy of doxorubicin while minimizing the side effects like cardiac toxicity and myelosuppression.13,14 The results of the studies evaluating PLD have never matched those of its parent drug, but with a safer side effect profile, in certain circumstances, it is preferable.
Spec (Investigators) Positive_regulation (evaluated) of use associated with sarcoma, leiomyosarcoma and cv unclassified under development
3) Confidence 0.12 Published 2010 Journal Core evidence Section Body Doc Link PMC2899778 Disease Relevance 1.09 Pain Relevance 0
Some people felt that they already knew harm reduction messages and that they had "no use" for more harm reduction information that was provided in the kit.
Positive_regulation (had) of no use
4) Confidence 0.12 Published 2008 Journal Harm Reduct J Section Body Doc Link PMC2613138 Disease Relevance 0.09 Pain Relevance 0
The current supply is based on a semi-synthetic process.16 It is a tetrahydroiso-quinoline alkaloid that binds to the minor groove of DNA and selectively inhibits DNA transcription17 and assembly of the microtubular cytoskeleton.17,18 At the cellular level, trabectedin blocks cell cycle progression in the G2/M phase through a p-53-independent apoptotic process which effectively inhibits transcriptional activation of inducible genes.19

Clinical evidence for the use of trabectedin in the treatment of STS

Positive_regulation (activation) of use in groove associated with sarcoma and apoptosis
5) Confidence 0.11 Published 2010 Journal Core evidence Section Body Doc Link PMC2899778 Disease Relevance 1.19 Pain Relevance 0.07
Nonetheless, accumulating evidence of undesirable effects has led regulatory authorities to mandate increasing restrictions on the use of epoetin beta and other ESAs.
Positive_regulation (increasing) of use
6) Confidence 0.08 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697520 Disease Relevance 0.31 Pain Relevance 0.07
However, the therapeutic use of melatonin, which is offered as a supplement in the US, is restricted by its low bioavailability.
Positive_regulation (restricted) of use associated with bioavailability
7) Confidence 0.07 Published 2010 Journal Core evidence Section Body Doc Link PMC2899775 Disease Relevance 0.19 Pain Relevance 0.34
No prolonged studies were performed as it was assumed that these diagnostic agents were injected only once—without taking into consideration the wide extension of indications, increased use also in case of follow-up studies (multiple sclerosis, oncology, CE-MRA) or the delayed elimination rate in case of renal insufficiency.
Positive_regulation (increased) of use associated with multiple sclerosis and renal insufficiency
8) Confidence 0.05 Published 2007 Journal MAGMA Section Body Doc Link PMC2797854 Disease Relevance 0.68 Pain Relevance 0.14
Therefore Omniscan® should not be used in these populations.Neonates and infants:Due to immature kidney function in neonates and infants up to 1 year of age, Omniscan® should only be used in these patients after careful consideration.Undesirable effects:Cases of NSF have been reported with Omniscan®.All other gadolinium — containing contrast agent s should add strong warnings about potential NSF with the following proposed SPC wording :Special warnings and precautions for use:There have been reports of NSF associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR < 30 ml/min per 1.73 m2).
Positive_regulation (precautions) of use in kidney associated with fibrosis
9) Confidence 0.04 Published 2007 Journal MAGMA Section Body Doc Link PMC2797854 Disease Relevance 0.59 Pain Relevance 0.26
Concomitant use of immunosuppressants does not appear to be necessary.


Positive_regulation (necessary) of use
10) Confidence 0.03 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012434 Disease Relevance 0.24 Pain Relevance 0.06
In addition, prospective studies with greater follow-up periods are necessary to verify the long-term safety of PRP, as the use of the growth factor preparation rhPDGF-BB has been associated with an increased risk of mortality in patients with a history of malignancy and is not recommended for use in these patients.
Neg (not) Positive_regulation (recommended) of use associated with malignant neoplastic disease
11) Confidence 0.02 Published 2010 Journal The Yale Journal of Biology and Medicine Section Body Doc Link PMC2844688 Disease Relevance 0.85 Pain Relevance 0
In addition, prospective studies with greater follow-up periods are necessary to verify the long-term safety of PRP, as the use of the growth factor preparation rhPDGF-BB has been associated with an increased risk of mortality in patients with a history of malignancy and is not recommended for use in these patients.
Neg (not) Positive_regulation (recommended) of use associated with malignant neoplastic disease
12) Confidence 0.02 Published 2010 Journal The Yale Journal of Biology and Medicine Section Body Doc Link PMC2844688 Disease Relevance 0.75 Pain Relevance 0
As the use of PRP increases, additional studies may establish PRP as an efficacious treatment modality and guide future treatment of chronic diabetic foot ulceration.



Positive_regulation (increases) of use in foot associated with diabetic foot ulcer
13) Confidence 0.02 Published 2010 Journal The Yale Journal of Biology and Medicine Section Abstract Doc Link PMC2844688 Disease Relevance 0.35 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox